In its attempt to find the reason for the high cost of Epipens, “Behind the Push to Keep Higher Priced Epipen in Consumer’s Hands” ignores the most obvious fact: Mylan raised prices 600%.

Instead it implies the problem is Pharmacy Benefit Managers (PBMs) encouraging plan sponsors to promote the expensive brand version over the generic.

The article is fundamentally flawed since it considers only the initial sticker price of the brand, not what plans actually pay after getting rebates and discounts. The net cost of some brands can be less expensive than the generic.

That’s a pretty big piece of missing information and renders this article uninformative and misleading.